XML 57 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Operating activities      
Net loss $ (15,917) $ (16,982) $ (16,911)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 744 922 853
Stock-based compensation 2,541 1,850 1,828
Changes in revaluation of warrant liability (2,059) (486) (39)
Gain on non-controlling equity interest 0 0 (315)
Non-cash interest expense 20 5 152
Deferred income taxes 62 0 0
Changes in operating assets and liabilities, net of effects of acquired business:      
Accounts receivable 1,652 (1,304) (1,167)
Inventories (3,740) (601) 2,066
Other assets (1,663) (13) 99
Accounts payable 2,506 1,450 (1,193)
Accrued restructuring 0 0 (113)
Accrued liabilities 1,971 (336) 569
Deferred revenue (34) (137) (97)
Net cash used in operating activities (13,917) (15,632) (14,268)
Investing activities      
Purchases of furniture, equipment and leasehold improvements (81) (158) (1,692)
Sales (purchases) of certain other assets (1) 55 (11)
Sales of investments 0 0 88
Maturities of investments 287 666 1,545
Net cash provided by (used in) investing activities 205 563 (70)
Financing activities      
Net proceeds from equity incentives and the exercise of warrants 332 143 370
Net proceeds from public offering 14,226 9,273 19,291
Proceeds from landlord provided leasehold incentives 0 0 1,561
Proceeds from revolving line of credit 1,810 2,300 0
Proceeds from debt, net of discount 0 4,910 4,811
Payments on revolving line of credit (920) 0 0
Payments on debt and landlord provided leasehold incentives (537) (5,008) (34)
Net cash provided by financing activities 14,911 11,618 25,999
Net increase (decrease) in cash and cash equivalents 1,199 (3,451) 11,661
Cash and cash equivalents, beginning of period 25,497 28,948 17,287
Cash and cash equivalents, end of period 26,696 25,497 28,948
Supplemental disclosures:      
Non-cash conversion of preferred stock to common stock 9,496 0 0
Common stock issued in connection with the acquisition of certain assets of BioOne 0 0 3,423
Cash paid for interest 460 1,024 600
Cash paid for income taxes $ 162 $ 125 $ 114